María Díez‐Campelo

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti et al. · New England Journal of Medicine · 2020 · 537 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes

Soraya Tabera, José Antonio Pérez‐Simón, María Díez‐Campelo et al. · Haematologica · 2008 · 277 citations · Full text

Life Sciences, Cell Biology, Immunology +13

Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification

Soraya Carrancio, Natalia López-Holgado, Fermín Sánchez‐Guijo et al. · Experimental Hematology · 2008 · 151 citations

Engineering, Biomedical Engineering, Cell Biology +16

Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q− syndrome

Olga López‐Villar, Fermín Sánchez‐Guijo, Cristina Robledo et al. · Leukemia · 2009 · 136 citations

Life Sciences, Genetics, Molecular Genetics +12

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

Uwe Platzbecker, Valeria Santini, Pierre Fenaux et al. · The Lancet · 2023 · 132 citations

Medicine, Hematology, Pharmacology +8